Dr Amit Sehrawat

Scopus Publications

Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India
Susheel Kumar Yeshala, Soumya Surath Panda, Lalatendu Moharana, SV Saju, Krishnakumar Rathinam, Susan Honey Raju, Amit Sehrawat, Deepak Sundriyal, Ashwin Oommen Phillip, Pamela Alice Kinsely, Kanu Priya Bhatia, Smita Kayal, Biswajit Dubashi, Sunu Lazar Cyriac, Sathya Natarajan, Lipsita Samantaray, Swati Sucharita Mohanty, Sudam Sadangi, Snehasis Pradhan, Arti Rana, Prasanth Ganesan
Journal of Ovarian Research, 2026
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a significant advancement in the maintenance treatment of advanced High-Grade Serous Ovarian Cancer (HGSOC), particularly in patients with BRCA mutations or Homologous Recombination Deficiency (HRD). While randomized trials have demonstrated their efficacy, real-world evidence from low- and middle-income countries (LMIC) like India remains scarce. This retrospective observational multicentre study aimed to assess the safety and effectiveness of first-line maintenance therapy with Olaparib or Rucaparib in Indian patients with BRCA-mutated (BRCAmut) or HRD-positive (HRD+) advanced HGSOC. RESULTS: The study evaluated data from 46 patients treated between May 2019 and December 2022 across six oncology centres under the BIRAC-supported Network of Oncology Clinical Trials of India. The median age was 50.5 years, with all having HGS histopathology. Stage III disease was present in 32(69.6%), and 12(26.1%) had a family history of cancer. Median turnaround time for gBRCA and HRD investigation was 18 and 20.5 days, respectively. BRCA1mut were seen in 30(65.2%), BRCA2 in 5(10.9%), and non-BRCA HRD + in 11(23.9%). Olaparib was given to 27(58.7%) and Rucaparib to 19(41.3%). At a median follow-up of 22.5 months (range 18–53), the median PFS was not reached. The 12 and 18-month PFS rates were 97.8% and 86.9%, respectively. No significant difference in mPFS was found between the two drugs or between BRCAmut and BRCA-wild HRD+ patients (NR vs. 29 months, p = 0.219) groups. Dose reductions were made in 18(39.1%) of patients due to toxicity [N = 9(50%)] or cost [N = 9(50%)], with no observed impact on PFS between the standard dose and the reduced dose. The major prevalent grade ≥ 3 toxicities comprised anaemia (13%), fatigue (6.5%), and thrombocytopenia (2.2%). CONCLUSION: Despite limitations of a retrospective design, this study supports the clinical efficacy and tolerability of PARPi in LMIC, with efficacy and toxicity outcomes comparable to global trial data. There were no statistically significant differences observed between Olaparib and Rucaparib, standard and reduced doses, or BRCAmut and HRD+ patients. This study supports the feasibility of incorporating PARPi into frontline maintenance therapy for advanced HGSOC in resource-limited environments.
Neoadjuvant docetaxel, cisplatin, and capecitabine in borderline-inoperable locally advanced oral cavity squamous cell carcinoma: A prospective observational study
Abhimanyu Singh, Manu Malhotra, Amit Sehrawat, Madhu Priya, Abhishek Bhardwaj, X. Joyson Antony, Ramesh Prasath, Devendra Singh Chawra, G. Vetrivel, Jyoti Choudhary
European Journal of Surgical Oncology, 2026
Primary Platinum-Resistant Ovarian Cancer: Clinicopathologic Correlates and Outcomes From a Multicenter Prospective Indian Registry
Amit Sehrawat, Lakhwinder Singh, Deepak Sundriyal, Shalini Rajaram, Sathya Natarajan, Aradhana Kumari, Soumya Surath Panda, Sunu Lazar Cyriac, Krishnakumar Rathnam, Ashwin Oommen Philips, Lalatendu Moharana, Lipsita Samantaray, Saju SV, Susheel Kumar Yeshala, Nishant Batta, Ashok Singh, Veena P, Latha Chaturvedula, Jayalakshmi D, Sunitha VC, Pradeep S, Pampa Ch Toi, Prasanth Ganesan
JCO Global Oncology, 2026
PURPOSE To identify clinicopathologic factors associated with primary platinum-resistant ovarian cancer and evaluate survival outcomes using data from a multicenter, prospectively maintained Indian cancer registry. MATERIALS AND METHODS Data were analyzed from a prospective database of Network of Oncology Clinical Trials in India registry from six tertiary care centers between January 2022 and December 2023. Primary platinum-resistant ovarian cancer was defined as progression during treatment or recurrence within 6 months of completing initial platinum-based chemotherapy. Demographic, clinical, and treatment variables along with survival outcomes were evaluated. RESULTS Among 367 women with newly diagnosed epithelial ovarian cancer treated with platinum-based chemotherapy, 62 (16.9%) had primary platinum-resistant ovarian cancer. The cohort had a mean age of 54 ± 11.2 years, 79% were postmenopausal, and 53.2% had Eastern Cooperative Oncology Group performance score ≥2. High-grade serous carcinoma histology predominated (75.8%), 90.3% presented with stage III to IV disease, 74.2% had ascites, and 79.1% had peritoneal spread. Debulking surgery was performed in 24.2%, platinum-taxane doublet was used in 83.9%, and among those receiving curative intent treatment, 88.1% received chemotherapy in the neoadjuvant setting. Maintenance therapy was received by 6.5%; none entered clinical trials. Over a median follow-up of 10.32 months, median progression-free and overall survival were 4.75 (95% CI, 4 to 6) and 9.33 (95% CI, 6.2 to 16.3) months, respectively, from baseline at diagnosis. Primary platinum resistance was associated with poor performance status, ascites, advanced stage, omission of debulking surgery, neoadjuvant chemotherapy, and palliative-intent chemotherapy ( P < .05). CONCLUSION Primary platinum resistance affected 16.9% of Indian women with epithelial ovarian cancer and was linked to poor performance status, advanced stage, omission of debulking surgery, neoadjuvant chemotherapy, and dismal survival outcomes underscoring the urgent need for better predictive and therapeutic strategies.
Real-World Experiences of Next-Generation Sequencing in Oncology: From an Indian Multicenter Registry and Collaborative Centers
Ashwin Oommen Philips, Soumya Surath Panda, Sunu Cyriac, Lalatendu Moharana, Sindhu Kilaru, et al.
Indian Journal of Medical and Paediatric Oncology, 2026
Abstract The integration of next-generation sequencing (NGS) in guiding personalized therapy for oncology faces the challenges, primarily, of cost and drug accessibility. Limited data from Indian academic centers accentuate the need for comprehensive insights into the real-world applications of NGS in oncology. The Network of Oncology Clinical Trials in India (NOCI), accessible at www.noci-india.com, compiled data on patients who underwent NGS for solid organ cancers from January 1, 2018, to December 31, 2021. This study aimed to elucidate the testing indications, sample types analyzed, and the resultant impact on patient care. Analysis of data from six centers included 278 subjects, with 24 specimens (9%) excluded due to quality test failure. Tissue constituted 59.7% of specimens, blood 38.5%, and both 1.8%. Predominantly, NGS was employed for identifying BRCA1/2 mutations (56%) and for targeted therapy in non-small-cell lung cancer (NSCLC; 28%). Only 41 (16%) patients with other cancers underwent multigene NGS panels in pursuit of targetable mutations. Among them, 13 exhibited targetable mutations, and 3 received treatment based on NGS findings. This study underscores that the majority of NGS applications focused on screening for BRCA1/2 mutations and identifying targetable mutations in NSCLC. However, among those undergoing NGS for advanced cancers, only a limited number received personalized therapy. The findings underscore the challenges of utilizing NGS in off-label indications within resource-constrained settings.
“Treatment Patterns and Survival Outcomes in Periampullary Carcinoma: A Multicentric Retrospective Study from the Indian Subcontinent”
Amit Sehrawat, Karthik Jayalingappa, Parmod Kumar, Soumya Surath Panda, Reetu Singhal, Sumit Subhadarshi Mohanty, Antara Sanyal, N. Arumugam, Krishnakumar Rathnam, S. V. Saju, H. S. Raju, Sathya Natarajan, S. Subhashree, M. K. Selvaraj, M. Sajid, Amit Gupta, Deepak Sundriyal
Indian Journal of Surgical Oncology, 2026
Refining early detection of hepatocellular carcinoma: The promise of the GALAD score
Harsha S P, Amit Sehrawat, Anusha Mruthyunjaya Swamy, Deepak Sundriyal
World Journal of Gastroenterology, 2026
This letter discusses the original article by Villa et al , published in the World Journal of Gastroenterology . Our primary focus is on the GALAD score, its components, standardization, and population-specific variations. We also attempted to discuss the current applications of GALAD score and how combining it with imaging modalities like ultrasound could improve it. Hepatocellular carcinoma (HCC) is still one of the leading causes of cancer death, and early detection is crucial to its prognosis. Current surveillance methods, like alpha-fetoprotein (AFP) and ultrasound, are not very specific, especially when it comes to metabolic-associated steatotic liver disease. Gender, age, AFP, AFP-L3, and des-gamma-carboxy prothrombin are all included in the operator-independent, non-invasive GALAD score, which has become a promising biomarker-based diagnostic tool for HCC. Population-specific cut-points with high sensitivity and specificity have been proposed by multicenter studies like Villa et al , particularly for differentiating between HCC and cirrhosis and healthy controls. However, there is no universal threshold due to variation across etiology, population, and assay technology. GALAD must be a context-sensitive auxiliary in the clinical setting, guiding surveillance intervals and imaging choices while improving predictive performance through serial measurement. Early detection is further improved by integration with imaging modalities, such as the GALADUS score. Standardized biomarker techniques and prospective, multi-ethnic validation are required for broad clinical use and optimal HCC surveillance.
A Patient with Adenocarcinoma Stomach on FLOT (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) Chemotherapy Presents with Tooth Discoloration: Spot the Diagnosis
Mayank Kapoor, Deepak Sundriyal, Amit Sehrawat
Indian Journal of Medical and Paediatric Oncology, 2026
Revisiting the use of steroids in oncology
Sai Prasath, S. P. Harsha, Anusha Mruthyunjaya Swamy, Karthik Jayalingappa, Mayank Kapoor, Deepak Sundriyal, Amit Sehrawat, Uttam Kumar Nath
Medical Oncology, 2026
Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers
Y. Yanthan, L. Pandey, A. Pandey, R. Pasricha, D. Joseph, S. Gupta, A. Sehrawat, A. Dhyani, M. Gupta
Clinical Oncology, 2026
Rechallenge-Confirmed Severe Periorbital Edema Following Sunitinib Therapy in Metastatic Renal Cell Carcinoma
Harsha S. Prakash, Sai Prasath, Deepak Sundriyal, Amit Sehrawat
Indian Journal of Surgical Oncology, 2026
Epidemiology, Treatment Patterns, and Survival Outcomes in Patients With Uterine Cancer in a Real-World Setting in India
Shalini Bose, Kavita Khoiwal, Shalini Rajaram, Amrita Gaurav, Rajlaxmi Mundhra, Anupama Bahadur, Nilotpal Chowdhury, Ashok Singh, Sweety Gupta, Deepa Joseph, Amit Sehrawat, Deepak Sundriyal, Parish Kamdi, Jaya Chaturvedi
Indian Journal of Surgical Oncology, 2026
Association between insulin resistance biomarkers and metastatic prognosis in treatment-naïve colorectal cancer patients: a pilot study
M. P. Narayanan, Amit Sehrawat, Bela Goyal, Parmod Kumar, Shashank Bansal, Satyanker Gupta, Amit Gupta, Anissa A. Mirza, Deepak Sundriyal, Sweety Gupta
BMC Cancer, 2025
Upfront surgery versus induction chemotherapy followed by surgery in oral cavity squamous cell cancers with advanced nodal disease (SurVIC Trial): A phase 3 multicentre randomised controlled trial
Dharma Ram Poonia, Amit Sehrawat, Jeewan Ram Vishnoi, Nivedita Sharma, Parmod Kumar, Bharti Devnani, Aparna Warriere, Akanksha Solanki, Puneet Pareek, Divya Aggarwal, Taruna Yadav, Prem Prakash Sharma, Ashita Gadwal, Anushka Goyal, Poonam Elhence, Pushpinder Khera, Ashish Jakhetiya, Pnahindra Swaim, Dillip Muduly, Rohit Mahajan, Pankaj Garg, Vijay Kumar, Madhabananda Kar, Sanjeev Misra
BMJ Open, 2025
Perspective of females from a rural community in India toward the knowledge, screening, and treatment of breast and cervical cancer and preventive vaccination
Deepak Sundriyal, Yogesh Bahurupi, Shalini Rajaram, Mahendra Singh, Pradeep Aggarwal, Preeti Antil, Sweety Gupta, Amit Sehrawat
Cancer Causes and Control, 2025
Effects of Chemotherapy on Fertility and Fertility Preservation Strategies for the Women of Childbearing Potential Undergoing Chemotherapy: A Comprehensive Review
Mayank Kapoor, Anusha Mruthyunjaya Swamy, Deepak Sundriyal, Mridul Khanna, Nishant Sinha, Karthik J, Shalini Rajaram, Amit Sehrawat
Indian Journal of Surgical Oncology, 2025
A Multicenter Study on the Challenges and Real-World Utilization of Immune Checkpoint Inhibitors in Resource-Constrained Settings: Insights and Implications from India
Ashwin Oommen Philips, Sunu Cyriac, P. Unnikrishnan, Anil T. Jose, Krishnakumar Rathnam, S.V. Saju, Smita Kayal, Soumya Surath Panda, Lalatendu Moharana, Sindhu Kilaru, Amit Sehrawat, Deepak Sundriyal, Puneet Dhamija, Deepak Jain, Pamela Alice K., Jaineet Sachdeva, Nishant Batta, Raman Arora, Yogesh Arora, Harpreet Singh, Mridul Anand, Ishu Sharma, Prasanth Ganesan
South Asian Journal of Cancer, 2025
High Prevalence of Malnutrition in Geriatric Patients with Solid Organ Cancer - An Institutional Study
Ujjawal Kumar Shriwastav, Deepak Sundriyal, Mridul Khanna, Neethu Sunny, Amit Sehrawat, Minakshi Dhar
JCO Global Oncology, 2025
Comparison of the Effect of Weekly Cisplatin Versus Three Weekly Cisplatin in Concurrent Chemoradiotherapy of Head and Neck Cancer: A Pilot Study
Anushree Chaturvedi, Amit Sehrawat, Trivikrama Rao Mopidevi, K. M. Parthasarthy, Deni Gupta, Anuj Singh
Indian Journal of Otolaryngology and Head and Neck Surgery, 2025
Evidence versus practice involving universal acceptance of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Results from a tertiary care center in India
Shivcharan Navriya, H. Talwar, Ankur Mittal, Sunil Kumar, V. Panwar, Amit Sehrawat, A. Mandal
Indian Journal of Cancer, 2025
Prolonged Remission in Metastatic Ano-Rectal Malignant Melanoma With Single Agent Temozolomide
Anusha Mruthyunjaya Swamy, Deepak Sundriyal, Mayank Kapoor, Mridul Khanna, Ravi Hari Phulware, Kranthi Kumar Jandrasupalli, Ujjawal Shriwastav, Amit Sehrawat
Cancer Reports, 2025
Mutational signature differences in paired tissues of triple-negative breast cancer receiving neoadjuvant therapy: Preliminary analysis.
Hemavathi Baskarane, Mohit Kumar Divakar, Atul Batra, Akash Kumar, Biswajit Dubashi, Amit Sehrawat, Parmod Kumar, Ashutosh Mishra, Pranay Tanwar, Suhani Suhani, Brijesh Kumar, Sandeep Mathur, Vishakha Hooda
Journal of Clinical Oncology, 2025
Hodgkin Lymphoma Presenting as Pel–Ebstein Fever: A Case Report
Ujjawal Kumar Shriwastav, Deepak Sundriyal, Parmod Kumar, Amit Sehrawat
Cancer Reports, 2024
Factors Associated With Default of Treatment and Follow-Up Among Patients With Cancer: A Cross-Sectional Study From a Lower-Middle-Income Country
Deepak Sundriyal, Mayank Kapoor, Preeti Antil, Sweety Gupta, Parmod Kumar, Ujjawal Kumar Shriwastav, Amit Sehrawat
JCO Global Oncology, 2024
Maxillary Diffuse Large B-Cell Lymphoma Enshrouded as Osteomyelitis: A Case Report
Akansha Vyas, Ashi Chug, Amit Sehrawat, Saurabh Simre, Jasmine Porwal, Preeti Kolse
Journal of Maxillofacial and Oral Surgery, 2024
A synthetic bioactive peptide of the C-terminal fragment of adhesion protein Fibulin7 attenuates the inflammatory functions of innate immune cells in LPS-induced systemic inflammation
Saloni Gupta, Nibedita Dalpati, Shubham Kumar Rai, Amit Sehrawat, Venkatesh Pai, Pranita P. Sarangi
Inflammation Research, 2024
Interferons as Neoadjuvant Chemotherapy for Giant Cell Tumor: A Hospital-Based Prospective Pilot Study
Saroj prasad Sah, Anil Regmi, Bishwa Bandhu Niraula, Amit Sehrawat, Saroj Kumar Bhagat, et al.
Indian Journal of Medical and Paediatric Oncology, 2024
Carcinoma en Cuirasse as the heralding sign of underlying HER-2 positive male breast cancer
Mayank Kapoor, Deepak Sundriyal, Amit Sehrawat, Mridul Khanna
BMJ Case Reports, 2024
Adolescent and Young Adults with Gastric Cancer (AYA-GC)-The Dilemma of an Under-Represented Group: A Multi-Institutional Analysis from the Indian Subcontinent
S. S. Panda, S. S. Mohanty, A. Sanyal, P. Ganesan, S. Kayal, K. Rathnam, S. V. Saju, S. Cyriac, P. Unnikrishnan, A. Sehrawat, D. Sundriyal, A. Philips, D. Jain, S. S. Mohanty, S. K. Agrawal, L. Moharana, S. R. Choudhury, B. Dubashi
South Asian Journal of Cancer, 2024
Real-World Data on Treatment Outcome of ALK-Positive Non-Small Cell Lung Cancer from an Indian Multicentric Cancer Registry
Lalatendu Moharana, Soumya Surath Panda, Suma Devaraj, Ghanashyam Biswas, Ganesh Chandra Subudhi, Prasant Kumar Parida, Sourav Kumar Mishra, Jogamaya Pattnaik, Sambit Mohanty, Sukanya Karunanidhi, Sandhya Lakshmi Singuluri, S. V. Saju, Krishna Kumar Rathnam, Amit Sehrawat, Shikha Mudgal, Sunu Lazar Cyriac, Ashwin Philips, Anil Kumar Jose, Prasant Ganesan
South Asian Journal of Cancer, 2024
Prevalence and impact of endocrine disorders in advanced metastatic cancer patients undergoing cancer-directed therapy: A prospective observational study
Gaurav Karna, Amit Sehrawat, Saurabh Karna, Ravi Kant, Deepak Sundriyal, Summi Karn, Dipesh Jha
Cancer Reports, 2024
Spectrum of Cisplatin-Induced Cardiotoxicity in Dysgerminomas: Case Series and Review
Mayank Kapoor, Amit Sehrawat, Shalini Rajaram, Deepak Sundriyal
Indian Journal of Gynecologic Oncology, 2024
Beyond the Norm: Unraveling Sphenoidal Metastasis in Prostate Cancer – A Rare Encounter
Amit Sehrawat, Mridul Khanna, Deepak Sundriyal
Asian Pacific Journal of Cancer Care, 2024
Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment
Mayank Kapoor, Amit Sehrawat, Deepak Sundriyal
Indian Journal of Medical and Paediatric Oncology, 2024
Reply to A. Mathew et al
Amit Sehrawat, Mridul Khanna, Smita Kayal, Prasanth Ganesan
JCO Global Oncology, 2024
A novel ultra-performance liquid chromatography detection method development and validation for paclitaxel and its major metabolite in human plasma
Vikas Kumar, Gyan Vardhan, Amit Sehrawat, Shailendra Handu, Puneet Dhamija
Indian Journal of Pharmacology, 2024
Clinicopathologic Profile and Treatment Outcomes of Colorectal Cancer in Young Adults: A Multicenter Study from India
Amit Sehrawat, Mridul Khanna, Smita Kayal, Deepak Sundriyal, Shraddha Tiwari, Sunu Cyriac, Praveen Ravishankaran, Jomon Raphael, Dominic Mathew, Soumya Surath Panda, Laltendu Moharana, Sumit Subhadarshi Mohanty, Swati Sucharita Mohanty, Ashwin Philips, Deepak Jain, Pamela Jeyaraj, Parvez Haque David, Jaineet Patil, S.V. Saju, Krishnakumar Rathnam, Neha Sharma, Kaaviya Dheva, Sree Rekha Jinkala, Kalyarasaran Raja, Prasanth Penumadu, Prasanth Ganesan
JCO Global Oncology, 2024
A longitudinal cohort study on assessing the impact of COVID-19 pandemic on the mental health of cancer care providers: Developing world scenario
A. Thaduri, A. Sehrawat, D. Poonia, Anindya Das, Rajesh Kumar, A. Varghese, L. Chadha, R. Seenivasagam, P. Garg, Deepak Sundryal, M. Gupta
Journal of Head and Neck Physicians and Surgeons, 2023
Audit of In-Hospital Mortality from a Medical Oncology and Hemato-Oncology Center with the Emphasis on Best Supportive Care
Deepak Sundriyal, Uttam Kumar Nath, Parmod Kumar, Sweety Gupta, Deepa Joseph, Sudeep Vaniyath, Rituparna Chetia, Anamika Bakliwal, Debranjini Chattopadhyay, Gaurav Dhingra, Amit Sehrawat
South Asian Journal of Cancer, 2022
Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic
BMJ Global Health, 2022
Embracing geriatric assessment into the treatment plan: The earlier the better
Deepak Sundriyal, Amit Sehrawat
Cancer Research Statistics and Treatment, 2022
Chemotherapy in geriatric patients with poor performance status small cell lung cancer: Series from a tertiary care center
Deepak Sundriyal, Parmod Kumar, Ujjawal Kumar, Amit Sehrawat
Aging Medicine, 2022
An Institution-Based Demographic Study of Urinary Bladder Cancer from North India
Parmod Kumar, Samaksh Sharma, Deepak Sundriyal, Shiv Charan Navria, Amit Sehrawat
Indian Journal of Surgical Oncology, 2022
Exploring an Unfathomed Entiry: A Pooled Analysis of Solitory Skeletal Muscle Metastasis from Head and Neck Squamous Cell Carcinoma
Dharma Ram Poonia, Suhas Kodasoge Rajappa, Ajay K. Dewan, Amit Sehrawat, Chaturbhuj Agrawal, Koyyala Venkata Pradeep Babu
Journal of Maxillofacial and Oral Surgery, 2022
Ribociclib-induced hypocalcemia in metastatic breast cancer
A. Sehrawat, Parmod Kumar, D. Sundriyal
Indian Journal of Cancer, 2022
Addressing the challenges of head and neck cancer care in India – A compelling need of the hour
Abhinav Thaduri, Dilip Dungala, Achyuth Panuganti, Kinjal Shankar Majumdar, Amit Sehrawat
Oral Oncology, 2022
Totally Implantable Venous Access Device (Chemoport) in Oncology: Study of 168 Polyurethane Chemoport Catheter System
Gyanendra Swaroop Mittal, Deepak Sundriyal, Niranjan B. Naik, Amit Sehrawat
South Asian Journal of Cancer, 2021
Exceptional Responders in Gynecologic Oncology: A case series and review of literature
Pallavi verma, Amrita Gaurav, Sandipan Choudhuri, Shivaani Arora, Neha Kumari, Amit Sehrawat, Parmita Tiwari, Jaya Chaturwedi
Indian Journal of Gynecologic Oncology, 2021
Lung cancer screening: An unending tale
ManojKumar Gupta, DharmaRam Poonia, Amit Sehrawat
Journal of Cancer Research and Therapeutics, 2021
Bone Marrow Metastases from Solid Organ Cancer in Adults
Lima Arya, Deepak Sundriyal, Rekha Bhandari, Ruchi Srivastava, Amit Sehrawat
Indian Journal of Surgical Oncology, 2021
Paraneoplastic palmar fasciitis and polyarthritis syndrome in a metastatic breast cancer patient: Rare case report
Amit Sehrawat, Trivikram Rao, Lalit Sharma, KM Parthasarathy
Indian Journal of Medical and Paediatric Oncology, 2021
Efficacy and safety of folfox as a second-line chemotherapy for patients with locally advanced and/or metastatic carcinoma gall bladder - Experience from a tertiary care center in India
Ketan Dang, Deni Gupta, Amit Sehrawat, Satyanker Gupta, KM Parthasarathy
Indian Journal of Medical and Paediatric Oncology, 2021
Effect of dose and schedule of L-asparaginase administration on early minimal residual disease in acute lymphoblastic leukemia
Satyanker Gupta, Amit Sehrawat, Ketan Dang, Lalit Sharma, Sarita Jaiswal, Suparno Chakarbarti
Indian Journal of Medical and Paediatric Oncology, 2021
Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute
Amit Sehrawat, Gyanendra Swaroop Mittal, Deepak Sundriyal, Anushree Chaturvedi, Deni Gupta
Indian Journal of Surgical Oncology, 2021
Colonic metastases from a luminal a type invasive ductal carcinoma breast: A rare case report
Amit Sehrawat, Sumedha Ahal Kotwal, Deni Gupta
Indian Journal of Medical and Paediatric Oncology, 2021
Febrile neutropenia due to COVID-19 in an immunocompetent patient
Yumkham Monica Devi, Amit Sehrawat, Prasan Kumar Panda, Uttam Kumar Nath
BMJ Case Reports, 2021
Tripe palms and Malignant Acanthosis Nigricans: More than a diagnostic pointer
Parmod Kumar, Megha K Mukundan, Amit Sehrawat, Deepak Sundriyal
Cancer Reports, 2021
Leptomeningeal relapse in primary cutaneous DLBCL: Implications for a prophylactic CNS therapy
Deepak Sundriyal, Lima Arya, Ruchi Srivastava, Meenu Walia, Amit Sehrawat
Cancer Reports, 2021
Facial disfigurement due to olfactory neuroblastoma: beauty regained with chemotherapy
Parmod Kumar, Deepak Sundriyal, Rekha Bhandari, Abhijeet Singh, Bhinyaram Jat, Amit Sehrawat
Cancer Reports, 2021
Demographic and clinicopathological profile of gall bladder cancer patients: Study from a tertiary care center of the sub-himalayan region in indo-gangetic belt
Sweety Gupta, Amit Gupta, RohikAnjum T. Siddeek, JaineJohn Chennatt, Tanuj Singla, Deepak Rajput, Navin Kumar, Amit Sehrawat, Sanjeev Kishore, Manoj Gupta
Journal of Carcinogenesis, 2021
Grade as prognostic variable in early tongue cancer patients: Are we getting off the track?
Abhinav Thaduri, Amit Sehrawat, Dharma Ram Poonia, Mahendra Pal Singh, Nilotpal Chowdhury
Oral Oncology, 2020
Running an oncology day-care with guts and glory
Sundriyal Deepak, Sehrawat Amit, Manoj Gupta
Medical Oncology, 2020
Paraneoplastic Transaminitis—a Rare Manifestation of Ovarian Cancer
Laxman Pandey, Amit Sehrawat, Yanpothung Yanthan, Prashant Joshi, Manoj Gupta
Indian Journal of Surgical Oncology, 2020
Impact of COVID-19 Pandemic on Oncology Practices During Nationwide Lockdown Period: A Single Centre Experience and the Way Forward
Journal of the Association of Physicians of India, 2020
Tolerance and efficacy of branded generic pemetrexed maintenance in Indian patients of metastatic non-squamous non-small-cell lung cancer
Amit Sehrawat, KM Parthasarathy, Deni Gupta, Arun Gera
Indian Journal of Cancer, 2019
Metastatic dermatosis in breast carcinoma on adjuvant trastuzumab: Is skin a sanctuary site in human epidermal growth factor receptor-2-amplified disease?
Amit Sehrawat, SumedhaA Kotwal, KM Parthasarathy
Indian Journal of Dermatology, 2018
Gut colonization with carbapenem-resistant enterobacteriaceae adversely impacts the outcome in patients with hematological malignancies: Results of a prospective surveillance study
SUPARNO CHAKRABARTI
Mediterranean Journal of Hematology and Infectious Diseases, 2018
Prostatic Adenocarcinoma Incognito Manifestation as Generalized Lymphadenopathy: a Rare Case Report
Amit Sehrawat, Satyanker Gupta, Tiwari Alok
Indian Journal of Surgical Oncology, 2017
T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation
Sarita Rani Jaiswal, Shamsuz Zaman, Aditi Chakrabarti, Amit Sehrawat, Satish Bansal, Mahesh Gupta, Suparno Chakrabarti
Transplant Immunology, 2016
Two case reports of an unusual association between Klippel-Feil syndrome and amyotrophic lateral sclerosis: Do they share same genetic defect?
KoneruLakshmi Umamaheshwar, Amit Sehrawat, ManojK Parashar, Kshitij Mavade
Annals of Indian Academy of Neurology, 2013

Dr Amit Sehrawat

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS